Global Urticaria Drugs Market 2018-2022
About this market
Urticaria is a vastly prevalent disorder resulting in high medical consultations globally. The increase in risk factors for urticaria like latent infectious, chronic inflammatory diseases, autoreactivity and alcohol consumption. Though the incident is increasing, and it is negatively impacting the quality of life of the people, most patients are undertreated due to challenges in affordability of drugs and low access to healthcare due to social stigma. Technavio’s analysts have predicted that the urticaria drugs market will register a CAGR of over 10% by 2022.
Guidelines for management of urticaria patients
The management guidelines include clinical classification, etiology, investigations, diagnosis, treatment guidance along with special sections on children suffering from urticaria and the use of antihistamines in pregnant women or breastfeeding women.
High cost of urticaria management
The high medication costs along with the indirect costs are expected to put low- income patients at danger for suboptimal treatment and an increased burden due to poorly controlled disease.
For the detailed list of factors that will drive and challenge the growth of the urticaria drugs market during the 2018-2022, view our report.
The global urticaria drugs market is moderately concentrated and the market being in a growth phase, the competition among companies is intense. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Technavio Announces the Publication of its Research Report – Global Urticaria Drugs Market 2018-2022
Technavio recognizes the following companies as the key players in the global urticaria drugs market: F. Hoffmann-La Roche (Genentech), JDP Therapeutics, Meiji Holdings, Novartis, Taiho Pharmaceutical.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the introduction of biologics for the treatment of urticaria.”
According to the report, one of the major drivers for this market is the guidelines for management of urticaria patients.
Further, the report states that one of the major factors hindering the growth of this market is the high cost of urticaria management.
F. Hoffmann-La Roche (Genentech)
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook